Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

and heart rate for Empatic are similar to or more favorable than the placebo-subtracted changes observed with Contrave, and there are no signals of cardiovascular concern in the Empatic development program, reassuring results of a cardiovascular outcomes trial with Contrave will be sufficient. In addition, while the FDA reiterated the belief that the teratogenicity potential for zonisamide is very concerning, the FDA will allow Phase 3 studies of Empatic to include women of childbearing potential who have a Body Mass Index that meets the FDA definition of overweight (>27kg/m2) in the presence of at least one weight-related comorbidity. Orexigen owns worldwide rights to Empatic. Prior to initiating Phase 3 studies of Empatic, the Company plans to seek a collaboration partner to help fund further clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the second quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 35366685. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a key milestone in ... Knee System. ,   ... introduced the NexGen knee system, with its innovative design and ... of the NexGen knee have taken place worldwide. ... the importance of design innovation and component quality for surgeons and patients ...
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... , March 27, 2015  RXi ... privately-held MirImmune LLC, today announced that they ... to RXi,s novel and proprietary sd-rxRNA® technology ... immunotherapies. The collaboration has the potential to ... friendly cancer treatments that could be a ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... , LEXINGTON, Ky. , Feb. 1 ... it has completed the sale of secure data and messaging provider, ... Management Technologies, Inc. (OTC Bulletin Board: WNDM) as previously announced in ... sale of Secure eHealth, VHGI has also transferred all of the ...
... , Consumers Oppose Prescription Mandate; Prefer Alternative ... , Jan. 30 Mississippians are expressing outrage ... containing pseudoephedrine (PSE) to a prescription (Rx) drug. , ... number for Mississippians to contact their legislators which within the ...
Cached Medicine Technology:VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC 2VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC 3VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC 4Mississippians React to Rushed Pseudoephedrine Debate Raging in the State Legislature 2Mississippians React to Rushed Pseudoephedrine Debate Raging in the State Legislature 3
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... 28, 2015 The "Petrick Sustainable ... sustainable health. After 18 years of research and experience ... UFC contenders, Dr. Jon Petrick is excited to be ... some of the immediate benefits of this radical new ... levels of strength of the immune system, faster healing ...
(Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
(Date:3/27/2015)... Red Deer, Alberta (PRWEB) March 27, 2015 ... had, until then, prevented her from working, Monica K. arrived ... day in the mending department quiet, defensive and scared. The ... Employment Placement & Support Services (EPSS) to offer jobs ... it does take patience and a willingness to begin with ...
(Date:3/27/2015)... Mo (PRWEB) March 27, 2015 ... for patients undergoing percutaneous coronary intervention (PCI), resulting ... have observed a “risk-treatment paradox,” in which the ... from treatment are treated less often with bleeding ... at Saint Luke’s Mid America Heart Institute asked ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... quite common for a female song sparrow to stray from ... but a new study shows that sleeping around can be ... American Naturalist, found that offspring conceived outside sparrows, ... within-pair offspring. The findings throw a monkey wrench into theories ...
... of Environmental Health Sciences (NIEHS), part of the National ... Research Program (SRP) at the University of California, San ... grant will fund continued research on the molecular and ... and other hazardous waste sites. It is the ...
... By Maureen Salamon HealthDay Reporter , ... anticipated move sure to unleash heated debate, a prominent ... all ages no longer be screened for prostate cancer ... The U.S. Preventive Services Task Force, an independent group ...
... , TUESDAY, May 22 (HealthDay News) -- ... C virus could develop potentially life-threatening liver complications over ... Researchers evaluated medical insurance claims data and found ... liver disease in 2008, and estimated that another 300,000 ...
... When thousands of psychiatrists attend their field,s largest annual ... into drug treatments report overwhelmingly on positive results. ... in the Journal of Clinical Psychopharmacology by ... Yale University, who analyzed the presentations given at two ...
... The Food and Drug Administration has approved a new ... disorders. The test, or assay, was developed by an expert ... Lawrence Schwartz, M.D., Ph.D., chair of the Division of ... Professor of Medicine at VCU, has spent more than 30 ...
Cached Medicine News:Health News:For monogamous sparrows, it doesn't pay to stray (but they do it anyway) 2Health News:UC San Diego Superfund Research Program receives $15 million grant renewal 2Health News:U.S. Advisers Say 'No' to Routine PSA Tests for Prostate Cancer 2Health News:U.S. Advisers Say 'No' to Routine PSA Tests for Prostate Cancer 3Health News:Hepatitis C Causing Liver Damage in Greater Numbers: Study 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 3Health News:FDA clears test developed in partnership with VCU researcher 2
... ARK-760A is an Auto Refractor/Keratometer ... subjective refinement. Electronic elevation, automatic ... unequalled accuracy and all the ... the Marco Automatic Refractors/Keratometer famous, ...
Sterile perfluorocarbon for intraocular Application....
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: